ADDITIVE EFFECT OF CONTINUOUS LOW-DOSE OFLOXACIN ON ERYTHROMYCIN THERAPY FOR SINOBRONCHIAL SYNDROME

被引:20
作者
ISHIURA, Y
FUJIMURA, M
SAITO, M
SHIBATA, K
NOMURA, M
NAKATSUMI, Y
MATSUDA, T
机构
[1] Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa
关键词
D O I
10.1016/0954-6111(95)90135-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It has been established that long-term low-dose erythromycin therapy (EM therapy) is very effective for sinobronchial syndrome, a common condition in Japan characterized by chronic upper and lower airway inflammation. The effect does not result from its bacteriocidal activity and the detailed mechanisms are not known. It takes 3-6 months for EM therapy to improve the symptoms. This study was designed to evaluate the additive effect of continuous low dosage or intermittent usual dosage of ofloxacin (OFLX) on EM therapy in patients with sinobronchial syndrome. Patients with sinobronchial syndrome were randomly allocated to receive one of the following four regimens. Patients in Group A received both low-dose OFLX and EM therapy daily for 6 months. Patients in Group B received EM therapy and intermittent treatment of OFLX for 6 months. Patients in Group C underwent EM therapy for 6 months. Patients in Group D received neither OFLX nor EM therapy. All patients were given carbocystein for more than 2 months before starting each treatment and during the study period. In patients receiving OFLX and/or EM therapy, these antimicrobial agents were well-tolerated during the treatment period. Amount of sputum in the morning was significantly less in Group C than in Group D after 3-6 months, and decreased significantly in Group A as compared with Group B after 2 weeks, Group C after 2 weeks to 2 months, and Group D after 2 weeks to 6 months. Other symptoms such as number of expectorations, difficulty of expectoration and severity of cough also improved rapidly in Group A. These findings suggest that it is useful to add low-dose OFLX to EM therapy for sinobronchial syndrome, especially within 1-2 months from starting treatment, and it may be cost-effective as this combination therapy can shorten the treatment period of EM therapy.
引用
收藏
页码:677 / 684
页数:8
相关论文
共 26 条
[2]  
DODGE RR, 1980, AM REV RESPIR DIS, V122, P567
[3]   COUGH THRESHOLD TO INHALED TARTARIC ACID AND BRONCHIAL RESPONSIVENESS TO METHACHOLINE IN PATIENTS WITH ASTHMA AND SINO-BRONCHIAL SYNDROME [J].
FUJIMURA, M ;
SAKAMOTO, S ;
KAMIO, Y ;
SAITO, M ;
MIYAKE, Y ;
YASUI, M ;
MATSUDA, T .
INTERNAL MEDICINE, 1992, 31 (01) :17-21
[4]   CORRELATION OF NONSPECIFIC BRONCHIAL RESPONSIVENESS TO BASE-LINE PULMONARY-FUNCTION IN PATIENTS WITH ASTHMA AND SINOBRONCHIAL SYNDROME [J].
FUJIMURA, M ;
KAMIO, Y ;
HASHIMOTO, T ;
MATSUDA, T .
INTERNAL MEDICINE, 1993, 32 (01) :1-5
[5]  
Fujimura M, 1992, Clin Auton Res, V2, P397, DOI 10.1007/BF01831398
[6]   ERYTHROMYCIN INHIBITS RESPIRATORY GLYCOCONJUGATE SECRETION FROM HUMAN AIRWAYS INVITRO [J].
GOSWAMI, SK ;
KIVITY, S ;
MAROM, Z .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (01) :72-78
[7]   DIFFUSE PANBRONCHIOLITIS - A DISEASE OF THE TRANSITIONAL ZONE OF THE LUNG [J].
HOMMA, H ;
YAMANAKA, A ;
TANIMOTO, S ;
TAMURA, M ;
CHIJIMATSU, Y ;
KIRA, S ;
IZUMI, T .
CHEST, 1983, 83 (01) :63-69
[8]  
IINO Y, 1993, ARCH OTOLARYNGOL, V119, P648
[9]   GASTROINTESTINAL MOTOR-STIMULATING ACTIVITY OF MACROLIDE ANTIBIOTICS AND ANALYSIS OF THEIR SIDE-EFFECTS ON THE CANINE GUT [J].
ITOH, Z ;
SUZUKI, T ;
NAKAYA, M ;
INOUE, M ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (06) :863-869
[10]   A MECHANISM OF ERYTHROMYCIN TREATMENT IN PATIENTS WITH DIFFUSE PANBRONCHIOLITIS [J].
KADOTA, J ;
SAKITO, O ;
KOHNO, S ;
SAWA, H ;
MUKAE, H ;
ODA, H ;
KAWAKAMI, K ;
FUKUSHIMA, K ;
HIRATANI, K ;
HARA, K .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (01) :153-159